{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T12:54:15Z","timestamp":1769691255099,"version":"3.49.0"},"reference-count":15,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfus Med Hemother"],"published-print":{"date-parts":[[2015]]},"abstract":"<jats:p>&lt;b&gt;Background: &lt;\/b&gt;To assess the impact of safety measures, we compared reporting rates of transfusion-related reactions before and after the implementation of six measures in 1999, 2004, 2006, 2008 and 2009. &lt;b&gt;Methods:&lt;\/b&gt; Reporting rates of transfusion-transmitted bacterial infection (TTBI), viral infection (TTVI) and immune-mediated transfusion-related acute lung injury (TRALI) were calculated on the basis of confirmed annual reports and distributed blood components. &lt;b&gt;Results: &lt;\/b&gt;The introduction of HCV NAT testing caused a significant reduction of HCV reporting rate from 1:0.6 to 1:83.16 million administered blood components (p &lt; 0.0001), donor screening for antibodies to hepatitis B core antigen caused a reduction of HBV reporting rate from 1:2.90 to 1:10.70 million units (p = 0.0168). A significant reduction from 1:0.094 to 1:2.42 million fresh frozen plasma (FFP) units could also be achieved by risk minimisation TRALI measures (p &lt; 0.0001). Implementation of pre-donation sampling did not result in a significant decrease in TTBI, whereas limitation of shelf life for platelet concentrate (PC) minimised the TTBI reporting rate from 1:0.088 to 1:0.19 million PC units (p = 0.041). For HIV NAT pool testing, no significant reduction in HIV transmission was found due to very low reporting rates (1:10 million versus 1:27 million blood components, p = 0.422). &lt;b&gt;Conclusion:&lt;\/b&gt; On the basis of haemovigilance data, a significant benefit could be demonstrated for four of six implemented safety measures.<\/jats:p>","DOI":"10.1159\/000381996","type":"journal-article","created":{"date-parts":[[2015,7,23]],"date-time":"2015-07-23T21:01:26Z","timestamp":1437685286000},"page":"240-246","source":"Crossref","is-referenced-by-count":25,"title":["Evaluation of Risk Minimisation Measures for Blood Components - Based on Reporting Rates of Transfusion-Transmitted Reactions (1997-2013)"],"prefix":"10.1159","volume":"42","author":[{"given":"Markus B.","family":"Funk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarethe","family":"Heiden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Volkers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Lohmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Keller-Stanislawski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2015,5,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3148.2009.00947.x"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2001.41081020.x"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/j.0041-1132.2004.04347.x"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1438.2002.00053.x"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02212.x"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.0042-9007.2004.00410.x"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1159\/000330372"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.00746.x"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2010.01432.x"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2450\/2014.0175-13"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009072.pub2"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.01948.x"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.02652.x"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.02659.x"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2011.0469"}],"container-title":["Transfusion Medicine and Hemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/381996","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/381996","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:00:21Z","timestamp":1745431221000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000381996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":15,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,7,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000381996","archive":["Portico"],"relation":{},"ISSN":["1660-3796","1660-3818"],"issn-type":[{"value":"1660-3796","type":"print"},{"value":"1660-3818","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}